All In Biotech

BLA 761089 · Teva Pharms USA

Ajovy

Fremanezumab-Vfrm · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Sep 14, 2018

Approved uses

3

Original approval plus efficacy supplements

Registered trials

32

14 Phase 3, 6 recruiting

FAERS reports

11,839

3,963 serious, 117 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 5, 2026.

AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. ( 1 )

Mechanism: Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 5, 2025 Supplement 31 · Efficacy · priority review LabelLetter
  • Jan 27, 2020 Supplement 2 · Efficacy LetterLabel
  • Sep 14, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • AJOVY · FREMANEZUMAB-VFRM 150MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fremanezumab" as an intervention, any sponsor and status, largest first.

All 32 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • accidental exposure to product1,501
  • injection site pain1,358
  • migraine1,114
  • drug ineffective951
  • headache778
  • injection site erythema685
  • device leakage576
  • device malfunction521
  • fatigue518
  • nausea518
  • injection site pruritus511
  • injection site swelling462

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20163
20173
2018177
20191,390
20201,047
20211,421
20221,590
20231,420
20242,163
20251,484
20261,140

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 97 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.